Zydus Lifesci. Q1 FY27 Results (NSE: ZYDUSLIFE)
Signal: Margin pressure
The read
The quarter marks a sharp profitability inflection against the recent margin arc: revenue growth accelerated to 22.0% YoY from 5.9% in Q1FY26, but EBITDA margin contracted to 24.1% from 31.8%, reversing the prior quarter's 100bps expansion and driving net profit down 35.9% to ₹9,398 million. The thesis now depends on whether the branded and specialty expansion, including the upcoming Saroglitazar launch, can restore margins while North America recovers.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹8,017 Cr | 22.0% | 5.7% |
| Net profit | ₹939.8 Cr | -35.9% | |
| EBIT margin | 24.1% |
P&L walk
Consolidated revenue increased 22.0% YoY and 5.7% QoQ to ₹80,170 million, but EBITDA declined 7.6% YoY to ₹19,294 million and margin fell 770bps to 24.1%, pulling net profit down 35.9% YoY to ₹9,398 million.
Segments
Consumer Wellness was the main growth engine at ₹14,292 million revenue, up 67.2% YoY, while International Markets Formulations grew 34.0% to ₹9,735 million; North America, the largest disclosed business at ₹30,979 million, declined 2.6% YoY and restrained pharma growth to 8.6%.
Key positives
- Revenue was ₹80,170 million, up 22.0% YoY and 5.7% QoQ, accelerating from 5.9% YoY growth in Q1FY26.
- Consumer Wellness revenue increased 67.2% YoY to ₹14,292 million, led by 35% growth in skin and hair care and 16% growth in food and nutrition brands.
- International Markets Formulations revenue grew 34.0% YoY to ₹9,735 million, while India Formulations grew 19.5% to ₹18,158 million.
- R&D investment of ₹6,424 million represented 8% of revenues, alongside 11 new US product launches, 9 ANDA approvals and priority review for Saroglitazar in PBC.
- Net debt remained moderate at 0.22x equity and 0.70x EBITDA.
Key concerns
- EBITDA declined 7.6% YoY to ₹19,294 million even as revenue grew 22.0%, compressing EBITDA margin by 770bps to 24.1%.
- Net profit fell 35.9% YoY to ₹9,398 million and 26.1% QoQ, materially underperforming the revenue trajectory.
- North America Formulations revenue declined 2.6% YoY to ₹30,979 million despite accounting for 40% of consolidated business revenues, leaving the largest business weak.
- Consumer Wellness domestic growth was only 5% YoY, with seasonal brands declining amid a softer summer season.
Research and educational content only. Not investment advice.